In December 2020 Inceptua licensed the global commercial rights of Apealea from Elevar Therapeutics Inc.
Apealea is a cancer medicine containing the active substance paclitaxel, which belongs to a group of medicines called taxanes. Paclitaxel affects or stops growth of rapidly dividing cells, such as tumour cells.
Apealea is used to treat the following cancers in adults, in combination with another medicine called carboplatin:
- Epithelial ovarian cancer – a cancer of the ovary, the organ that produces a woman’s egg cells
- Primary peritoneal cancer – a cancer of the cells lining the space between the wall of the belly and the internal organs
- Cancer of the fallopian tubes (the connection between the ovaries and the womb)
It is used when other therapies have not worked.
The medicine can only be obtained with a prescription.
Reference Information
Apealea Patient Information Leaflet.
The European Medicines Agency (EMA) is an agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Apealea:
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Apealea please follow these links:
Medical Information
If you would like to speak to a medical representative, please contact:
inceptua.mi@primevigilance.com
+49 30 1202 1381
Safety and adverse events
Patient safety is a key priority for us. For any suspected adverse drug reactions associated with Apealea, please contact:
+49 30 1202 1381